DexCom price target lowered to $82 from $94 at Truist

Truist lowered the firm’s price target on DexCom (DXCM) to $82 from $94 and keeps a Buy rating on the shares. The company’s Q3 earnings and revenue beat was modest, but its light gross margins were “not as clean as hoped”, the analyst tells investors in a research note. Truist adds that it expects estimates to rebase lower, which may pressure shares further, the firm added.